The Ree Wynn Foundation Announces the First EL-PFDD for iTTP
Externally-Led Patient-Focused Drug Development (EL-PFDD) meetings give FDA and other key stakeholders, including medical product developers, health care providers, federal partners, an important opportunity to hear directly from patients, their families, caregivers, and patient advocates about the symptoms that matter most to them, the impact the disease has on patients’ daily lives, and patients’ experiences with currently available treatments. This input can inform the FDA’s decisions and oversight during drug development.
On January 26, 2024, The Ree Wynn Foundation will host the Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting.
The goal of this meeting is to provide the U.S. Food and Drug Administration (FDA), product developers, clinicians, and academic researchers an opportunity to hear perspectives from individuals with iTTP on the health effects and daily impacts of their iTTP, treatment goals, and decision factors considered when seeking out or selecting a treatment. This meeting is being conducted as a parallel effort to FDA’s PFDD initiative to more systematically gather patients’ perspectives on their conditions and available therapies to treat their conditions.”
The EL-PFDD is a half-day event that spans 4-5 hours. It will focus on patient voices through panel discussions.